Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Sarah Inglott

Senior Scientist - Study of Acute Infant leukaemia (SAIL Project)

  • The SAIL project aims to transform the outlook for infants with acute lymphoblastic leukaemia (iALL), and ultimately to contribute towards developing new treatments for infant and childhood leukaemia. My role is to adapt existing and develop new research methodologies and materials for diagnostic and follow up flow cytometry, and potentially develop and establish novel methods.

I became a state registered Healthcare Scientist in 1998 specialising in paediatric Haematological disease after studying at Westminster University and doing my in house training at Great Ormond Street Children’s Hospital. I rotated through all specialities of Haematology before taking the role of Lead Healthcare Scientist and Manager of Haematology Specialist Services. The Lab incorporated a Flow cytometry diagnostic service , PCR for Leukaemia associated translocations, Thrombotic mutations detection using allelic discrimination. Bone Marrow engraftment studies using FISH and Western blot, investigations for Red cell and platelet  pathologies and cryopreservation of autologous bone marrow or aphoresed cells for post ablative ‘rescue’ therapies.

From 2013 my role changed and became focussed on developing a multiparameter flow cytometry clinical service for paediatric haematological diseases. This later expanded to include solid tumour work, quantification of measurable residual disease (MRD) in paediatric leukaemia, identification of targets for CAR-T and immunotherapies with optimal quantification to reduce risk of leukaemia escape and subsequent evolution. Monitoring of efficacy of CAR-T and immunotherapies, identifying early relapse and leukaemia evolution in response to treatments.

While my background has been as a Healthcare Scientist I have also collaborated with numerous research groups over the years at ICH, UCL and the WIMM both in primary and translational research.